{name}
{subtitle}
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~23 mi. (Przemyśl, Poland, +93 more cities)
facility
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1053)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
city
~23 mi. (Przemyśl, Poland, +34 more cities)
facility
Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249)
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
city
~61 mi. (Brzozów, Poland, +72 more cities)
facility
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza
biomarker
del(11)(q10), +27 more biomarkers
condition
Primary Myelofibrosis, +1 more condition
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~69 mi. (Lviv, Ukraine, +144 more cities)
facility
Lviv State Regional Oncological Center ( Site 2712)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~69 mi. (Lviv, Ukraine, +176 more cities)
facility
Lviv State Regional Oncological Center ( Site 2361)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~69 mi. (Lviv, Ukraine, +147 more cities)
facility
Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0882)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~69 mi. (Lviv, Ukraine, +159 more cities)
facility
Lviv Regional Clinical Hospital ( Site 0955), +1 more facility
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~69 mi. (Lviv, Ukraine, +163 more cities)
facility
Lviv State Regional Oncological Center ( Site 0967), +1 more facility
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types